These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Keloids show regional distribution of proliferative and degenerate connective tissue elements. Bux S; Madaree A Cells Tissues Organs; 2010; 191(3):213-34. PubMed ID: 19641294 [TBL] [Abstract][Full Text] [Related]
7. Chondroitinase injection improves keloid pathology by reorganizing the extracellular matrix with regenerated elastic fibers. Ishiko T; Naitoh M; Kubota H; Yamawaki S; Ikeda M; Yoshikawa K; Fujita H; Yamaguchi H; Kurahashi Y; Suzuki S J Dermatol; 2013 May; 40(5):380-3. PubMed ID: 23451938 [TBL] [Abstract][Full Text] [Related]
8. Identification of unique gene expression patterns within different lesional sites of keloids. Seifert O; Bayat A; Geffers R; Dienus K; Buer J; Löfgren S; Matussek A Wound Repair Regen; 2008; 16(2):254-65. PubMed ID: 18282266 [TBL] [Abstract][Full Text] [Related]
9. Elevated prolidase activity in keloids: correlation with type I collagen turnover. Duong HS; Zhang QZ; Le AD; Kelly AP; Kamdar R; Messadi DV Br J Dermatol; 2006 May; 154(5):820-8. PubMed ID: 16634881 [TBL] [Abstract][Full Text] [Related]
10. The molecular basis of keloid and hypertrophic scar formation. Tuan TL; Nichter LS Mol Med Today; 1998 Jan; 4(1):19-24. PubMed ID: 9494966 [TBL] [Abstract][Full Text] [Related]
11. The keloid phenomenon: progress toward a solution. Louw L Clin Anat; 2007 Jan; 20(1):3-14. PubMed ID: 16944532 [TBL] [Abstract][Full Text] [Related]
12. Keloids: a new challenge for nutrition. Ferreira AC; Hochman B; Furtado F; Bonatti S; Ferreira LM Nutr Rev; 2010 Jul; 68(7):409-17. PubMed ID: 20591108 [TBL] [Abstract][Full Text] [Related]
13. Keloid and hypertrophic scarring may result from a mechanoreceptor or mechanosensitive nociceptor disorder. Ogawa R Med Hypotheses; 2008 Oct; 71(4):493-500. PubMed ID: 18614294 [TBL] [Abstract][Full Text] [Related]
14. The role of stem cell factor and c-KIT in keloid pathogenesis: do tyrosine kinase inhibitors have a potential therapeutic role? Mukhopadhyay A; Do DV; Ong CT; Khoo YT; Masilamani J; Chan SY; Vincent AS; Wong PK; Lim CP; Cao X; Lim IJ; Phan TT Br J Dermatol; 2011 Feb; 164(2):372-86. PubMed ID: 20846303 [TBL] [Abstract][Full Text] [Related]
15. [Pharmacological therapy of keloids in an athymic mouse model]. Blazek J; Ottomann C; Muehlberger T Handchir Mikrochir Plast Chir; 2008 Apr; 40(2):81-7. PubMed ID: 18437665 [TBL] [Abstract][Full Text] [Related]
16. Comparative study of keloid formation in humans and laboratory animals. Khorshid FA Med Sci Monit; 2005 Jul; 11(7):BR212-9. PubMed ID: 15990682 [TBL] [Abstract][Full Text] [Related]
18. Madecassoside suppresses migration of fibroblasts from keloids: involvement of p38 kinase and PI3K signaling pathways. Song J; Xu H; Lu Q; Xu Z; Bian D; Xia Y; Wei Z; Gong Z; Dai Y Burns; 2012 Aug; 38(5):677-84. PubMed ID: 22360962 [TBL] [Abstract][Full Text] [Related]
19. IL-6 signaling pathway in keloids: a target for pharmacologic intervention? Uitto J J Invest Dermatol; 2007 Jan; 127(1):6-8. PubMed ID: 17170717 [TBL] [Abstract][Full Text] [Related]
20. DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts. Makino S; Mitsutake N; Nakashima M; Saenko VA; Ohtsuru A; Umezawa K; Tanaka K; Hirano A; Yamashita S J Dermatol Sci; 2008 Sep; 51(3):171-80. PubMed ID: 18406579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]